ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 200 µg/ml - solution for injection - 100 mcg/0.5ml - active: darbepoetin alfa 200 µg/ml excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 200 µg/ml - solution for injection - 60 mcg/0.3ml - active: darbepoetin alfa 200 µg/ml excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 200 µg/ml - solution for injection - 80 mcg/0.4ml - active: darbepoetin alfa 200 µg/ml excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 25 µg/ml - solution for injection - 10 mcg/0.4ml - active: darbepoetin alfa 25 µg/ml excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 40 µg/ml - solution for injection - 15 mcg/0.375ml - active: darbepoetin alfa 40 µg/ml excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 40 µg/ml - solution for injection - 20 mcg/0.5ml - active: darbepoetin alfa 40 µg/ml excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 500 µg/ml - solution for injection - 150 mcg/0.3ml - active: darbepoetin alfa 500 µg/ml excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 500 µg/ml - solution for injection - 200 mcg/0.4ml - active: darbepoetin alfa 500 µg/ml excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 500 µg/ml - solution for injection - 300 mcg/0.6ml - active: darbepoetin alfa 500 µg/ml excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

amgen new zealand limited - darbepoetin alfa 500 µg/ml - solution for injection - 500 mcg/ml - active: darbepoetin alfa 500 µg/ml excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.